Solubility Advantage Marinosolv is a patent-protected platform that sharply improves solubility and bioavailability for poorly soluble compounds, enabling new therapies and making Marinomed a compelling partner for biotech and pharma assets facing formulation hurdles. Solv4U offers development support across all stages to de-risk programs and accelerate timelines.

Strategic Partnerships Recent activity includes a term sheet with Phargentis SA to develop a respiratory therapy using Marinosolv, with Marinomed providing specialized formulation services and technical expertise. This demonstrates a model for external collaborations and positions Marinomed as a potential partner for similar respiratory assets.

OINDP Capabilities Marinomed has active OINDP formulation development through its Solv4U unit, including collaboration with SPH Sine Pharmaceutical Laboratories. This creates opportunities to pursue inhalation and nasal/ophthalmic programs that require advanced solubility enhancement for oral inhaled products.

Therapeutic Focus With a concentration on respiratory and ophthalmic diseases, Marinomed can be a valuable partner for asset owners seeking delivery optimization and stability improvements for mucus-rich or ocular applications, including anti-inflammatory and immune-related indications.

Growth Readiness As a lean, EU-based biotech with a growing pipeline and recent leadership shifts, Marinomed appears receptive to contracted development, licensing, or co development deals. This suggests multiple entry points for BD teams to propose discovery support, formulation optimization, or joint venture opportunities.